CapsoVision, Inc.
CapsoVision, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 million, up 15.3% from fiscal 2024. In the quarter to June 2026, revenue grew 9.89%, EPS grew 92.6% and free cash flow fell 84.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow CV
CapsoVision, Inc. (CV) P/E ratio
As of 16 October 2026, CapsoVision, Inc. (CV) trades at a P/E ratio of 2.1×. Over the past ten years it has ranged from 0.0× (March 2026) to 5.8× (June 2026); the current reading is higher than 70% of that period. That is below the Medical Devices industry median of 23.2× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 2.4× | (57.18%) |
| Mar 2026 | 5.6× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 4 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SENS Senseonics Holdings, Inc. compare | n/m |
| OFIX ORTHOFIX MEDICAL INC. compare | n/m |
| CLPT ClearPoint Neuro, Inc. compare | n/m |
| QSI Quantum-Si Incorporated compare | n/m |
| RCEL Avita Medical Inc. compare | n/m |
| SI Shoulder Innovations, Inc. compare | n/m |
| CV CapsoVision, Inc. | 2.1× |
| VMD Viemed Healthcare, Inc. compare | 24.9× |
| INFU InfuSystems Holdings, Inc. compare | 31.7× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)